Evidence map›Paper›PMID 37366172›Full record

ArticleClinical trials (London, England)2023

Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.

Xiaofei Wang, Stephen L George

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaofei WangDepartment of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-7512-8445
Stephen L GeorgeDepartment of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3625-5852

Funding

Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Transforming Clinical Trials for Elderly and Rare Cancers through Intelligent and Robust Information BorrowingR01AG066883 · NIA · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Xiaofei Wang, Shu Yang · 2020 to 2026
$2.0M
NCI NIH HHS P01 CA142538NIA NIH HHS R01 AG066883
6 · The paper itself

Abstract

backgroundStandard futility analyses designed for a proportional hazards setting may have serious drawbacks when non-proportional hazards are present. One important type of non-proportional hazards occurs when the treatment effect is delayed. That is, there is little or no early treatment effect but a substantial later effect.

methodsWe define optimality criteria for futility analyses in this setting and propose simple search procedures for deriving such rules in practice.

resultsWe demonstrate the advantages of the optimal rules over commonly used rules in reducing the average number of events, the average sample size, or the average study duration under the null hypothesis with minimal power loss under the alternative hypothesis.

conclusionOptimal futility rules can be derived for a non-proportional hazards setting that control the loss of power under the alternative hypothesis while maximizing the gain in early stopping under the null hypothesis.

Indexed as

Medical FutilityResearch DesignHumansRandomized Controlled Trials as TopicSample SizeAverage hazard ratioclinical trial designdelayed treatment effectfutility rulesnon-proportional hazards

Identifiers

PMID37366172
PMCPMC10751393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.